This study suggests that targeting both the GLS pathway and the PHGDH pathway may represent a promising therapeutic strategy for patients with chemotherapy‐resistant gastric cancer, as validated in patient‐derived organoids. The gene discussed is GLS; the disease is gastric cancer.